AstraZeneca posts another Truqap study fail, says China import tax could triple

AstraZeneca’s Truqap is 2-for-4 in its pivotal cancer trials. It said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim analysis ...